Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC), Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT04335682
Phase: Phase 2
Trial Summary: This is a prospective, randomized, open-label phase II study comparing cognitive outcomes between men with non-metastatic and metastatic castration-resistant prostate cancer (mCRPC – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Alliance Foundation Trials, LLC.
Acronym: ARACOG

Pin It on Pinterest